German Healthcare Services Stock News

Evonik Industries (XTRA:EVK) posted a mixed set of results for investors, as EPS was pressured by a one-off €242 million loss over the past 12 months, dragging net profit margins down to 0.7% from 1.5% last year. Earnings have declined at an average annual rate of 32.4% over the past five years, but projections are turning heads. The company now expects earnings to grow 35.7% annually, which is significantly higher than the German market's 16.9% yearly growth forecast. While EVK's revenue...

As European markets experience mixed performances, with the STOXX Europe 600 Index recently pulling back slightly after reaching new highs, investors are closely watching for signals from the European Central Bank amid stable inflation rates. In this environment, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those looking to navigate uncertain market conditions.

Key Insights Geratherm Medical's estimated fair value is €4.22 based on 2 Stage Free Cash Flow to Equity Geratherm...

While Wacker Neuson SE ( ETR:WAC ) might not have the largest market cap around , it saw significant share price...

When you see that almost half of the companies in the Machinery industry in Germany have price-to-sales ratios (or...

Wondering if Fresenius SE KGaA is truly a bargain or just riding the wave? You're not alone. The stock's value is a hot topic for investors eyeing healthcare giants. After soaring 43.5% year-to-date, with a 41.7% gain over the last year, it's clear things are moving. However, the past week has seen a 5.0% pullback, adding a dose of short-term volatility to the mix. Recent headlines have revolved around Fresenius advancing its strategic transformation, including portfolio streamlining and a...

Wondering if Deutsche Bank's incredible stock gains still leave room for value? You are not alone. We are about to decode what the numbers reveal. After climbing 1.8% in the last week, 5.9% over the past month, and an eye-watering 88.2% year-to-date, the stock has grabbed plenty of attention as momentum builds. The surge has been driven by upbeat industry sentiment and regulatory changes favoring European banks. Investor optimism around large financial institutions has also risen in the wake...

Elmos Semiconductor (XTRA:ELG) posted earnings growth of 21.5% over the last year, outpacing its current net profit margin of 22.2% compared to 17.2% in the previous period. Shares recently traded at €90.4, above an estimated fair value of €78.5 according to a discounted cash flow model. The stock’s Price-to-Earnings ratio of 12.5x stands well below peer and industry averages. With revenue expected to grow at 9.1% annually and margins expanding, the latest results underscore a compelling mix...

Hugo Boss (XTRA:BOSS) posted a net profit margin of 5.3%, up modestly from 5.1% a year ago, with EPS growth for the year coming in at 4.2%, which is notably softer than its 5-year average of 38.9% annually. Looking ahead, revenue is set to grow at 3.8% per year and earnings at 8.2%, both running behind the broader German market averages of 6.1% and 16.9% respectively. This round of results shows steady, if not spectacular, profitability trends for the company, with investors likely turning...

Nemetschek (XTRA:NEM) delivered earnings growth of 19.5% over the last year, handily outpacing its 5-year average of 11.5% per year. Net profit margin stands at 17.6%, a touch below last year’s 18.5%, with earnings expected to continue rising faster than the German market at 18.4% per year ahead. With solid growth forecasts and no flagged risks, investors will be weighing the strong growth outlook, high-quality earnings, and fair value discount against a premium Price-To-Earnings Ratio that...

NORMA Group (XTRA:NOEJ) is expected to see revenue growth of 4.6% per year, which trails the broader German market’s 6.1% annual pace. The company remains unprofitable, with losses increasing at an average rate of 27.1% per year over the past five years. However, the outlook is brighter as analysts project a turnaround to profitability within three years, supported by robust expected earnings growth of 113.46% per year. In this context, the stock’s current valuation appears attractive...

Fresenius Medical Care (XTRA:FME) expects earnings to grow at 17.43% per year, backed by revenue projected to expand 4.1% annually. The company’s net profit margin has edged up to 3.7% from 3.4% a year ago. Earnings have also reversed a five-year decline of 17% per year to grow 9% over the past year. With shares trading at €41.76 and a price-to-earnings ratio of 16.8x, which is well below both peers and the European healthcare sector average, these numbers signal renewed momentum and...

Nordex (XTRA:NDX1) continued its remarkable earnings improvement, with profitability rising at an annual rate of 20.3% over the past five years and a dramatic jump of 384.7% in the latest year. Net profit margins climbed to 1.5%, up from 0.3% a year earlier. Revenue is forecast to grow 7.1% annually, topping the 6.1% pace of the wider German market. With earnings projected to increase 33.7% per year going forward, the company stands out for both ongoing growth and a strong margin turnaround...

Innoscripta (XTRA:1INN) continues its strong run with net profit margins climbing to 40.4%, up from 36.6% last year, and a substantial 82.2% earnings growth over the past year. This performance is well ahead of its already impressive five-year average of 44% per year. Looking forward, analysts expect both revenue and earnings to rise at rapid clips of 24.7% and 27.2% per year, respectively, outpacing the broader German market. Investors will likely view this momentum, paired with a share...

Schaeffler (XTRA:SHA0) currently faces rising losses, with net losses having grown 28.8% per year over the last five years and no reported improvement in net profit margin over the past twelve months. However, the company’s revenue is forecast to grow 3.6% per year, which trails the German market’s pace of 6.1%. Expectations are for a striking turnaround, with earnings projected to grow 135.4% annually and a return to profitability within three years. As investors weigh risks around financial...

Redcare Pharmacy NV, on October 28, 2025, reported sales of €2.15 billion and a net loss of €8.71 million for the first nine months of 2025, while also reaffirming unchanged earnings guidance for the full year with expected total sales growth exceeding 25%. The sharp year-on-year growth in sales alongside a significant reduction in net loss points to continued operational progress and confidence in sustained business momentum. We'll explore how the reaffirmation of strong sales growth...

Ever looked at Commerzbank and wondered if its surging share price means it's still a bargain, or if you've missed the boat? You're in the right place to find out what its real value might be. The stock has taken off this year, up a massive 109.3% year-to-date and delivering an impressive 101.3% gain over the last 12 months. This performance has caught the attention of both growth and value investors. Recent headlines have highlighted renewed momentum in Germany’s financial sector...

Wondering if Bayerische Motoren Werke is a smart buy right now? You are not alone, and there is a lot to unpack when it comes to figuring out whether the stock offers genuine value. The stock’s performance has been a mix of short-term volatility and longer-term growth, with a 16.7% gain over the past year and a 2.8% climb so far in 2024, despite recent dips in the last month. Recent headlines have focused on BMW’s ongoing investments in electric vehicles and strategic global partnerships,...

Wondering if Deutsche Telekom is a bargain right now? If you care about getting value for your money, it is smart to dig deeper into how this stock stacks up. The share price has dipped by 8.2% over the last week and is down 8.7% year-to-date, but has delivered an impressive 112.9% total return over the last five years. Recent headlines highlight ongoing expansion in their 5G network and strategic moves to strengthen their position in European telecom. Both of these factors are fueling...

Wondering if Siemens Healthineers is trading at a great price or if you are chasing the story too late? You are not alone. Let's dig into what the current market is saying. The stock has nudged up 0.8% over the past week and managed a steady 3.5% gain for the year, signaling renewed interest and possibly shifting risk perceptions. Recent news around advancements in medical imaging technology and key partnerships have been grabbing headlines, giving investors more to weigh as the company...

Over the past week, HD Hyundai announced a Memorandum of Understanding with Siemens to jointly drive digital transformation and modernize the U.S. shipbuilding industry, while Siemens also expanded partnerships with Capgemini for AI-native solutions in manufacturing and implemented advanced hydrogen monitoring platforms with H2SITE across Europe. These collaborations highlight Siemens' pivotal role in advancing industrial digitalization, through smart automation, data-driven efficiency, and...

AIXTRON SE recently reported third quarter 2025 earnings, showing sales of €119.56 million and net income of €13.03 million, both declining from the prior-year period; full-year guidance was also lowered, with revenue now expected between €530 million and €565 million, gross margin around 40% to 41%, and EBIT margin between 17% and 19%. This downward revision in outlook, attributed in part to foreign exchange effects and softer market conditions, highlights the impact of industry headwinds...

SAP (XTRA:SAP) shares have seen some movement lately, reflecting shifting sentiment in the broader tech sector. Investors appear to be weighing recent performance and potential valuation opportunities as the software company navigates the current economic climate. See our latest analysis for SAP. SAP’s share price has drifted lower over the past quarter, reflecting a mix of short-term caution and some profit-taking after strong multi-year gains. Still, with a 1-year total shareholder return...

Curious about whether BASF stock is a real bargain or just looks cheap at first glance? You are not alone, as questions about its true value have sparked plenty of debate among investors lately. BASF’s share price has edged slightly lower this year, down 1.8% year-to-date, and has been broadly flat over the past year, returning just 0.1%. Recent market movements reflect heightened attention to the company's strategic decisions and industry headwinds, including increased input costs and...